|
KMID : 0988920120100030244
|
|
Intestinal Research
2012 Volume.10 No. 3 p.244 ~ p.250
|
|
|
Frequency of Bone Marrow Toxicity by Using Pattern of Azathioprine in Inflammatory Bowel Disease Patients
|
|
Hyun Kyung-Hee
Lee Suck-Ho
Shin Jae-Min
Park Dong-Il
Lee Chang-Kyun
Shin Jeong-Eun
Eun Chang-Soo
Huh Kyu-Chan
Hwangbo Young
|
|
|
Abstract
|
|
|
Background/Aims: The most important adverse effect of azathioprine (AZA) is bone marrow toxicity (BMT). Many physicians have preferred a gradual dose increment (GDI) policy for the prevention of BMT. The aim of this study was to evaluate the efficacy of GDI for the prevention of AZA-induced BMT in inflammatory bowel disease (IBD) patients.
Methods: The medical records of IBD patients who received AZA in 6 university hospitals were reviewed. The patients were divided into two groups: the GDI group (initial dose ＜1.5 mg/kg, gradually increased to a therapeutic dose) and the non-GDI group (initial therapeutic dose ≥2 mg/kg).
Results: A total of 308 patients were enrolled (male to female ratio, 1:2.3; mean age, 34.91±14.19 years; ulcerative colitis, 43.5%; Crohn’s disease, 55.2%; and intermediate colitis, 1.3%). The overall incidence of BMT was 16.2% (50/308). BMT developed most frequently between fourth to eighth week (26%, 13/50). The rate of BMT of the non-GDI group was significantly higher than that of the GDI group (27.5%, 11/40 vs. 14.6%, 39/268, P=0.038). A multivariate analysis showed that the only factor related to BMT was a non-GDI policy (P=0.036; odds ratio, 2.41; 95% confidence interval, 1.06-5.49).
Conclusions: A GDI policy could be useful for reducing AZA-induced BMT in Korean IBD patients.
|
|
|
KEYWORD
|
|
|
Inflammatory Bowel Diseases, Azathioprine, Bone Marrow Toxicity
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|
|